Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19

Yuto Unoh; Shota Uehara; Kenji Nakahara; Haruaki Nobori; Yukiko Yamatsu; Shiho Yamamoto; Yuki Maruyama; Yoshiyuki Taoda; Koji Kasamatsu; Takahiro Suto; Kensuke Kouki; Atsufumi Nakahashi; Sho Kawashima; Takao Sanaki; Shinsuke Toba; Kentaro Uemura; Tohru Mizutare; Shigeru Ando; Michihito Sasaki; Yasuko Orba; Hirofumi Sawa; Akihiko Sato; Takafumi Sato; Teruhisa Kato; Yuki Tachibana

doi:10.1021/acs.jmedchem.2c00117

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

dose-dependently inhibited intrapulmonary replication of SARS-CoV-2 in mice, indicating that this novel noncovalent inhibitor could be a potential oral agent for treating COVID-19.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Unoh et al. (2022) studied this question.

synapsesocial.com/papers/6a00d65564548b97a42d9252 https://doi.org/10.1021/acs.jmedchem.2c00117

View Full Paper

Ask AI

Bookmark

Share

Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19

Ask about this paper

Abstract

Discussion

Cite This Study

Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading